Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | CA1 | P00915 | 12/20 | 0.55 |
| ▸ | CA2 | P00918 | 12/20 | 0.55 |
| ▸ | CA12 | O43570 | 11/20 | 0.55 |
| ▸ | CA9 | Q16790 | 11/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540289 | 0.87 | MEN1 (1.00) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2981652 | 0.85 | MEN1 (0.97) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2970463 | 0.85 | MEN1 (0.78) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2981850 | 0.84 | MEN1 (0.76) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2983698 | 0.84 | MEN1 (0.76) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL21791583 | 0.84 | MEN1 (0.76) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2981227 | 0.84 | MEN1 (0.76) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL13204695 | 0.84 | MEN1 (0.70) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2979747 | 0.83 | MEN1 (0.78) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL13204698 | 0.82 | MEN1 (0.69) | MEN1KMT2ACA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7700635-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-7700635-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-7700635-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-7230019-B2 | Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.